To include your compound in the COVID-19 Resource Center, submit it here.

QLT starts Phase III NSCLC trials

QLT (QLTI; TSE:QLT) started two double-blind North American and European Phase III trials of tariquidar (XR9576) as

Read the full 176 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE